Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 11/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 2/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2710062 | 1.00 | MCL1 (0.46) | MCL1CYP2D6CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL7407670 | 1.00 | MCL1 (0.46) | MCL1CYP2D6CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL14143865 | 1.00 | MCL1 (0.46) | MCL1CYP2D6CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL20239088 | 1.00 | MCL1 (0.46) | MCL1CYP2D6CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6847660 | 1.00 | MCL1 (0.46) | MCL1CYP2D6CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13481726 | 0.91 | MCL1 (0.44) | MCL1CYP2D6CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1890321 | 0.91 | MCL1 (0.44) | MCL1CYP2D6CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3187965 | 0.91 | MCL1 (0.44) | MCL1CYP2D6CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30148070 | 0.91 | MCL1 (0.44) | MCL1CYP2D6CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL11300131 | 0.91 | MCL1 (0.46) | MCL1HSD11B1UCHL1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281332-A1 | PROCESS FOR PRODUCING ESTER OR ALCOHOL | MITSUI CHEMICALS, INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2039680-A1 | PROCESS FOR PRODUCING ESTER OR ALCOHOL | Mitsui Chemicals, Inc. (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-6770741-B1 | USEFUL IN TREATING CONDITIONS AND DISEASES OF A MAMMAL AND HUMAN IN WHICH AN EXCESS OF BRADYKININ OR RELATED KININS ARE PRODUCED OR INJECTED SUCH AS BY INSECT BITES | SCIOS INC. | 2004-08-03 | — | — | US | disclosed |
| US-6288036-B1 | ANTIINFLAMMATORY, ANTIASTHMATIC, ANTIALLERGEN, AND ANALGESIC AGENTS; ARGININE-CONTAINING NONA- OR DECAPEPTIDES | SCIOS INC. | 2001-09-11 | — | — | US | disclosed |
| EP-0618810-B1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-0618809-B1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5543496-A | NONAPEPTIDE; ANTIINFLAMMATORY AGENTS, ANALGESICS | SCIOS NOVA INC. (US) | 1996-08-06 | — | — | US | disclosed |
| US-5385889-A | Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist | SCIOS NOVA INC. (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994019372-A1 | CYCLIC BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281332-A1 | PROCESS FOR PRODUCING ESTER OR ALCOHOL | ADH5, ADH1A, ADH1C | MCL1 4177/4885CYP2D6 149/4885CYP1A2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.